首页 > 最新文献

Expert Review of Vaccines最新文献

英文 中文
Multiple antigen presenting system (MAPS): state of the art and potential applications. 多重抗原递呈系统(MAPS):最新技术和潜在应用。
IF 6.2 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.1080/14760584.2023.2299384
Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer

Introduction: Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.

Areas covered: This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.

Expert opinion: The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.

导言:技术创新在推动疫苗设计和保护作用方面发挥了重要作用。安全性、耐受性和效力/有效性方面的改进大大降低了疫苗可预防的全球性疾病的发病率和死亡率。在此,我们介绍一种独创的疫苗平台--多抗原呈递系统(MAPS),它依赖于生物素化多糖(PS)与融合了根瘤菌素的病原体特异性蛋白之间的高亲和力相互作用。MAPS 允许灵活组合各种 PS 和蛋白质成分:本综述概述了 MAPS 的基本原理,并介绍了其在非临床和临床环境中用于设计针对细菌和病毒病原体的疫苗的应用:专家观点:MAPS利用高亲和力的非共价生物素-水苏碱相互作用,可在单一疫苗中结合多种PS和疾病特异性蛋白抗原。模块化设计可简化疫苗成分的交换。已发表的研究表明,MAPS 技术可支持更高的免疫原性广度(覆盖更多血清型,诱导 B 细胞和 T 细胞反应),超过 PS 疫苗或基于蛋白质的结合疫苗所能激发的免疫原性广度。重要的是,需要对基于 MAPS 的候选疫苗进行更详细的特征描述,尤其是在临床研究中。预计基于 MAPS 的疫苗可适用于多种具有全球公共卫生重要性的疾病。
{"title":"Multiple antigen presenting system (MAPS): state of the art and potential applications.","authors":"Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer","doi":"10.1080/14760584.2023.2299384","DOIUrl":"10.1080/14760584.2023.2299384","url":null,"abstract":"<p><strong>Introduction: </strong>Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.</p><p><strong>Areas covered: </strong>This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.</p><p><strong>Expert opinion: </strong>The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells. 从癌症疫苗中提取治疗性单克隆抗体 NEO-201,该抗体针对人类恶性肿瘤和免疫抑制细胞。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-01 DOI: 10.1080/14760584.2024.2397011
Massimo Fantini, Kwong Y Tsang, Philip M Arlen

Introduction: Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.

Areas covered: This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.

Expert opinion: To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer.

简介接种疫苗后产生的抗体可以通过分离和进一步筛选,开发出针对肿瘤相关抗原的高度特异性和强效单克隆抗体(mAbs):本综述介绍了不同类型的癌症疫苗、Hollinshead 癌症疫苗平台生成 mAb NEO-201 的过程、NEO-201 识别抗原的特征、NEO-201 通过 ADCC 和 CDC 结合并介导杀伤癌细胞和免疫抑制细胞(gMDSCs 和 Tregs)的能力、NEO-201 临床前和临床毒性与疗效:专家观点:为了克服癌症疫苗因免疫抑制细胞的活性而导致临床疗效不佳的问题,癌症疫苗可以与其他能够消耗免疫抑制细胞的免疫疗法相结合。NEO-201单独或与pembrolizumab联合使用的临床试验结果表明,治疗后疾病的持久稳定是由于NEO-201能够靶向减少循环Tregs和gMDSCs的百分比。
{"title":"Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells.","authors":"Massimo Fantini, Kwong Y Tsang, Philip M Arlen","doi":"10.1080/14760584.2024.2397011","DOIUrl":"10.1080/14760584.2024.2397011","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.</p><p><strong>Areas covered: </strong>This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.</p><p><strong>Expert opinion: </strong>To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. 2022 年美国爆发脊髓灰质炎疫情后未被发现的脊髓灰质炎病毒传播模型。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-01-04 DOI: 10.1080/14760584.2023.2299401
Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson

Background: New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.

Research design and methods: Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).

Results: With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.

Conclusions: In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.

背景:纽约州(NYS)报告了一例脊髓灰质炎病例(2022 年 6 月)和输入性 2 型循环疫苗衍生脊髓灰质炎病毒(cVDPV2)疫情(最后一次阳性废水检测时间为 2023 年 2 月),目前仍存在未检测到的潜在传播的不确定性:我们对先前的确定性模型进行了扩展,采用成熟的随机建模方法来描述 cVDPV2 无传播(CNC)的置信度与最后一次检测到传播信号(即脊髓灰质炎病毒阳性急性弛缓性脊髓炎病例或废水样本)后时间的函数关系:由于监测范围覆盖了纽约州的大部分人口,且重点关注疫情爆发县,根据监测灵敏度和人口混合模式,建模结果表明在最后一次监测信号呈阳性后的 3-10 个月内 CNC(95%)较高。监测灵敏度的不确定性意味着需要更长的时间才能达到较高的 CNC:结论:在脊髓灰质炎灭活疫苗(IPV)免疫覆盖率较高的人群中,未接种疫苗的个体可能会出现罕见的脊髓灰质炎病例。模型分析表明,此类疫情不太可能重新形成地方性传播或导致大量麻痹病例。实现并保持 IPV 的高免疫覆盖率仍然是预防疫情爆发和缩短输入性脊髓灰质炎病毒传播持续时间的最有效措施。
{"title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States.","authors":"Dominika A Kalkowska, Kamran Badizadegan, Janell A Routh, Cara C Burns, Eli S Rosenberg, I Ravi Brenner, Jane R Zucker, Marisa Langdon-Embry, Kimberly M Thompson","doi":"10.1080/14760584.2023.2299401","DOIUrl":"10.1080/14760584.2023.2299401","url":null,"abstract":"<p><strong>Background: </strong>New York State (NYS) reported a polio case (June 2022) and outbreak of imported type 2 circulating vaccine-derived poliovirus (cVDPV2) (last positive wastewater detection in February 2023), for which uncertainty remains about potential ongoing undetected transmission.</p><p><strong>Research design and methods: </strong>Extending a prior deterministic model, we apply an established stochastic modeling approach to characterize the confidence about no circulation (CNC) of cVDPV2 as a function of time since the last detected signal of transmission (i.e. poliovirus positive acute flaccid myelitis case or wastewater sample).</p><p><strong>Results: </strong>With the surveillance coverage for the NYS population majority and its focus on outbreak counties, modeling suggests a high CNC (95%) within 3-10 months of the last positive surveillance signal, depending on surveillance sensitivity and population mixing patterns. Uncertainty about surveillance sensitivity implies longer durations required to achieve higher CNC.</p><p><strong>Conclusions: </strong>In populations that maintain high overall immunization coverage with inactivated poliovirus vaccine (IPV), rare polio cases may occur in un(der)-vaccinated individuals. Modeling demonstrates the unlikeliness of type 2 outbreaks reestablishing endemic transmission or resulting in large absolute numbers of paralytic cases. Achieving and maintaining high immunization coverage with IPV remains the most effective measure to prevent outbreaks and shorten the duration of imported poliovirus transmission.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11284832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom. 模拟在英国使用改良疫苗接种不同 COVID-19 强化剂量疫苗策略可能产生的公共卫生和经济影响。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1080/14760584.2024.2383343
Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang

Background: Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).

Methods: A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.

Results: Vaccination targeting individuals aged ≥ 65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths, 18,086 hospitalizations, 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.

Conclusions: Targeting individuals aged ≥ 65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.

背景:更新疫苗对于抗击新出现的冠状病毒病2019(COVID-19)变种至关重要。本研究评估了英国加强接种改良疫苗对公共卫生和经济的影响:马尔可夫决策树模型估算了英国针对不同年龄和风险群体的疫苗接种策略的结果。模型使用了从公开资料中获得的特定年龄数据。该模型估算了病例数、死亡人数、住院人数、医疗成本和社会成本。为探讨不确定性,还进行了情景分析:针对年龄≥65 岁的个体和 12-64 岁的高危人群接种疫苗,估计可避免 701,549 例症状病例、5,599 例死亡、18,086 例住院、56,326 例 COVID 后病例和 38,263 例质量调整生命年 (QALY) 损失,直接和社会成本节约分别为 112,174,054 英镑和 542,758,682 英镑。在每 QALY 20,000 英镑和 30,000 英镑的支付意愿阈值下,从支付方角度估算的经济合理价格分别为 43 英镑和 61 英镑,从社会角度估算的经济合理价格分别为 64 英镑和 82 英镑。将研究范围扩大到更多年龄组可提高对公共健康的影响:结论:以年龄≥65 岁和 12-64 岁的高风险人群为目标可获得公共健康收益,但扩大到更多年龄组可获得额外收益。
{"title":"Modeling the potential public health and economic impact of different COVID-19 booster dose vaccination strategies with an adapted vaccine in the United Kingdom.","authors":"Cale Harrison, Rebecca Butfield, Ben Yarnoff, Jingyan Yang","doi":"10.1080/14760584.2024.2383343","DOIUrl":"10.1080/14760584.2024.2383343","url":null,"abstract":"<p><strong>Background: </strong>Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose of an adapted vaccine in the United Kingdom (UK).</p><p><strong>Methods: </strong>A Markov-decision tree model estimated the outcomes of vaccination strategies targeting various age and risk groups in the UK. Age-specific data derived from published sources were used. The model estimated case numbers, deaths, hospitalizations, medical costs, and societal costs. Scenario analyses were conducted to explore uncertainty.</p><p><strong>Results: </strong>Vaccination targeting individuals aged ≥ 65 years and the high-risk population aged 12-64 years was estimated to avert 701,549 symptomatic cases, 5,599 deaths, 18,086 hospitalizations, 56,326 post-COVID condition cases, and 38,263 lost quality-adjusted life years (QALYs), translating into direct and societal cost savings of £112,174,054 and £542,758,682, respectively. The estimated economically justifiable price at willingness-to-pay thresholds of £20,000 and £30,000 per QALY was £43 and £61, respectively, from the payer perspective and £64 and £82, respectively, from the societal perspective. Expanding to additional age groups improved the public health impact.</p><p><strong>Conclusions: </strong>Targeting individuals aged ≥ 65 years and those aged 12-64 years at high risk yields public health gains, but expansion to additional age groups provides additional gains.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune mechanisms targeting malaria transmission: opportunities for vaccine development. 针对疟疾传播的免疫机制:疫苗开发的机遇。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-25 DOI: 10.1080/14760584.2024.2369583
Geetha P Bansal, Nirbhay Kumar

Introduction: Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination.

Areas covered: In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector.

Expert opinion: To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.

导言:疟疾仍然是全球主要的健康问题,2022 年临床病例将近 25 亿,死亡人数超过 6 万。疫苗研发工作已取得重大进展,但已批准的疫苗疗效不佳,需要多次免疫接种,因此需要继续努力改进疫苗。不过,迄今取得的进展为消除疟疾提供了动力:在这篇综述中,我们将重点关注针对人类宿主配子体的各种免疫机制,以及配子体通过蚊媒介导的疟疾传播:要实现消灭疟疾的目标,关键是要针对蚊子传播疟疾的过程,这一过程完全由从受感染脊椎动物宿主体内摄取的有性阶段(即雄性和雌性配子体)介导。几十年来的研究已经确定,在蚊子中肠中发育的寄生虫有性阶段中的抗原是开发传播阻断疫苗(TBV)的诱人靶标。脊椎动物宿主体内配子细胞的免疫清除可与 TBV 协同作用,直接帮助维持有效的传播,降低免疫潜能。
{"title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development.","authors":"Geetha P Bansal, Nirbhay Kumar","doi":"10.1080/14760584.2024.2369583","DOIUrl":"10.1080/14760584.2024.2369583","url":null,"abstract":"<p><strong>Introduction: </strong>Malaria continues to remain a major global health problem with nearly a quarter of a billion clinical cases and more than 600,000 deaths in 2022. There has been significant progress toward vaccine development, however, poor efficacy of approved vaccines requiring multiple immunizing doses emphasizes the need for continued efforts toward improved vaccines. Progress to date, nonetheless, has provided impetus for malaria elimination.</p><p><strong>Areas covered: </strong>In this review we will focus on diverse immune mechanisms targeting gametocytes in the human host and gametocyte-mediated malaria transmission via the mosquito vector.</p><p><strong>Expert opinion: </strong>To march toward the goal of malaria elimination it will be critical to target the process of malaria transmission by mosquitoes, mediated exclusively by the sexual stages, i.e. male, and female gametocytes, ingested from infected vertebrate host. Studies over several decades have established antigens in the parasite sexual stages developing in the mosquito midgut as attractive targets for the development of transmission blocking vaccines (TBVs). Immune clearance of gametocytes in the vertebrate host can synergize with TBVs and directly aid in maintaining effective transmission reducing immune potential.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants. 源于 Vero 细胞培养的日本脑炎疫苗的免疫原性和安全性:中国婴儿的 3 期研究。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-24 DOI: 10.1080/14760584.2024.2404633
Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu

Background: Japanese encephalitis (JE) is a severe infectious disease of the central nervous system. Vaccination with Vero cell culture-derived vaccines may effectively reduce JE incidence.

Research design and methods: In this single-center, randomized, blinded, positive-controlled clinical trial in China involving 600 healthy infants aged 6-11 months, participants were divided into experimental and control groups administered JEV-PI and JEV-LI, respectively. Antibody titers were determined after 0- and 7-day immunization schedules. A booster dose followed 12 months later.

Results: After primary vaccination and before booster vaccination, the positive conversion rate, geometric mean titer (GMT), and geometric mean increase (GMI) of JEV-PI-neutralizing antibodies exceeded those of JEV-LI. After booster immunization, the GMT and GMI of JEV-PI were higher than those of JEV-LI. After primary immunization, the local, systemic, and overall adverse reactions were of grades 1 and 2, with a low incidence of grade 3. After booster immunization, these differences were mainly grades 1 and 2, with no differences between JEV-PI and JEV-LI.

Conclusion: JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.

Trial registration: The trial was registered in the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj = 203130; registration number: ChiCTR2300074692; registration date: 14/08/2023).

背景:日本脑炎(JE)是一种严重的中枢神经系统传染病。接种源于 Vero 细胞培养的疫苗可有效降低日本脑炎的发病率:在这项在中国进行的单中心、随机、盲法、阳性对照临床试验中,600 名 6-11 个月大的健康婴儿被分为实验组和对照组,分别接种 JEV-PI 和 JEV-LI。在 0 天和 7 天免疫接种后测定抗体滴度。12 个月后进行加强免疫:结果:在初次接种后和加强免疫前,JEV-PI 中和抗体的阳性转换率、几何平均滴度(GMT)和几何平均增加值(GMI)均超过了 JEV-LI。加强免疫后,JEV-PI的GMT和GMI均高于JEV-LI。初次免疫后,局部、全身和总体不良反应为 1 级和 2 级,3 级发生率较低。加强免疫后,不良反应主要为 1 级和 2 级,JEV-PI 和 JEV-LI 之间没有差异:结论:JEV-PI是一种很有前景的疫苗,因为婴儿在接种JEV-PI后可获得持久的高中和免疫抗体:该试验已在中国临床试验注册中心注册(https://www.chictr.org.cn/showproj.html?proj = 203130;注册号:ChiCTR2300074692):ChiCTR2300074692;注册日期:2023年8月14日)。
{"title":"Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants.","authors":"Huanhuan Wang, Juan Wang, Shijie Yan, Gengfan Zhao, Shanzhen Wang, Hong Tao, Ye Xu, Jinfeng Wu","doi":"10.1080/14760584.2024.2404633","DOIUrl":"10.1080/14760584.2024.2404633","url":null,"abstract":"<p><strong>Background: </strong>Japanese encephalitis (JE) is a severe infectious disease of the central nervous system. Vaccination with Vero cell culture-derived vaccines may effectively reduce JE incidence.</p><p><strong>Research design and methods: </strong>In this single-center, randomized, blinded, positive-controlled clinical trial in China involving 600 healthy infants aged 6-11 months, participants were divided into experimental and control groups administered JEV-PI and JEV-LI, respectively. Antibody titers were determined after 0- and 7-day immunization schedules. A booster dose followed 12 months later.</p><p><strong>Results: </strong>After primary vaccination and before booster vaccination, the positive conversion rate, geometric mean titer (GMT), and geometric mean increase (GMI) of JEV-PI-neutralizing antibodies exceeded those of JEV-LI. After booster immunization, the GMT and GMI of JEV-PI were higher than those of JEV-LI. After primary immunization, the local, systemic, and overall adverse reactions were of grades 1 and 2, with a low incidence of grade 3. After booster immunization, these differences were mainly grades 1 and 2, with no differences between JEV-PI and JEV-LI.</p><p><strong>Conclusion: </strong>JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.</p><p><strong>Trial registration: </strong>The trial was registered in the Chinese Clinical Trial Registry (https://www.chictr.org.cn/showproj.html?proj = 203130; registration number: ChiCTR2300074692; registration date: 14/08/2023).</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of cell-based influenza vaccine in France. 法国细胞流感疫苗的成本效益。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-24 DOI: 10.1080/14760584.2024.2417854
Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo

Objectives: Annually in France, influenza results in over one million GP consultations, around 20,000 hospitalizations, and approximately 9,000 deaths. This study assesses the cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) for those under 65, which enhances effectiveness avoiding egg-adaptation, compared to egg-based quadrivalent influenza vaccine (QIVe).

Methods: An age-structured susceptible-exposed-infected-recovered (SEIR) transmission model, calibrated to represent an average influenza season based on French data from 2011 to 2019, integrates a contact matrix estimating intergroup contact rates. Evaluating epidemiological, economic and utility outcomes, the model includes vaccine effectiveness and medical costs from the existing literature and French national data. Adjustments to quality of life due to infection and hospitalization are also included. Uncertainty is explored through scenario and sensitivity analyses.

Results: Compared to QIVe, QIVc significantly reduces healthcare utilization and mortality, preventing 49,946 GP consultations, 1,087 hospitalizations, and 231 deaths in France. Despite an initial investment of 7.6 million euros, QIVc achieves a net saving of 12 million euros in healthcare expenditures, making it a dominant cost-saving strategy. Probabilistic sensitivity analyses indicate dominance in 78% of 10,000 simulations.

Conclusions: Introducing cell-based influenza vaccines in the French immunization program prevents influenza cases, hospitalizations, death, while reducing costs versus egg-based influenza vaccines.

目标:法国每年因流感导致的全科医生就诊人数超过 100 万,住院人数约 2 万,死亡人数约 9000。本研究评估了针对 65 岁以下人群的细胞型四价流感疫苗(QIVc)与鸡蛋型四价流感疫苗(QIVe)的成本效益:方法:根据法国2011年至2019年的数据,校准了一个年龄结构的易感-暴露-感染-康复(SEIR)传播模型,以代表一个平均流感季节,该模型整合了一个估计群体间接触率的接触矩阵。该模型评估了流行病学、经济和效用结果,包括现有文献和法国国家数据中的疫苗效果和医疗成本。此外,还包括对感染和住院造成的生活质量的调整。通过情景分析和敏感性分析探讨了不确定性:结果:与 QIVe 相比,QIVc 显著降低了医疗保健的使用率和死亡率,在法国预防了 49,946 次全科医生会诊、1,087 次住院治疗和 231 例死亡。尽管初始投资为 760 万欧元,但 QIVc 净节省了 1200 万欧元的医疗开支,成为一种主要的成本节约策略。概率敏感性分析表明,在10,000次模拟中,有78%的人认为QIVc占优势:结论:在法国免疫计划中引入细胞型流感疫苗可预防流感病例、住院治疗和死亡,同时与鸡蛋型流感疫苗相比可降低成本。
{"title":"Cost-effectiveness of cell-based influenza vaccine in France.","authors":"Gaetan Gavazzi, Marc Paccalin, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin Mould-Quevedo","doi":"10.1080/14760584.2024.2417854","DOIUrl":"10.1080/14760584.2024.2417854","url":null,"abstract":"<p><strong>Objectives: </strong>Annually in France, influenza results in over one million GP consultations, around 20,000 hospitalizations, and approximately 9,000 deaths. This study assesses the cost-effectiveness of cell-based quadrivalent influenza vaccine (QIVc) for those under 65, which enhances effectiveness avoiding egg-adaptation, compared to egg-based quadrivalent influenza vaccine (QIVe).</p><p><strong>Methods: </strong>An age-structured susceptible-exposed-infected-recovered (SEIR) transmission model, calibrated to represent an average influenza season based on French data from 2011 to 2019, integrates a contact matrix estimating intergroup contact rates. Evaluating epidemiological, economic and utility outcomes, the model includes vaccine effectiveness and medical costs from the existing literature and French national data. Adjustments to quality of life due to infection and hospitalization are also included. Uncertainty is explored through scenario and sensitivity analyses.</p><p><strong>Results: </strong>Compared to QIVe, QIVc significantly reduces healthcare utilization and mortality, preventing 49,946 GP consultations, 1,087 hospitalizations, and 231 deaths in France. Despite an initial investment of 7.6 million euros, QIVc achieves a net saving of 12 million euros in healthcare expenditures, making it a dominant cost-saving strategy. Probabilistic sensitivity analyses indicate dominance in 78% of 10,000 simulations.</p><p><strong>Conclusions: </strong>Introducing cell-based influenza vaccines in the French immunization program prevents influenza cases, hospitalizations, death, while reducing costs versus egg-based influenza vaccines.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The important lessons lurking in the history of meningococcal epidemiology. 脑膜炎球菌流行病学史中潜藏的重要教训。
IF 6.2 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2024-04-04 DOI: 10.1080/14760584.2024.2329618
Ray Borrow, Jamie Findlow

Introduction: The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.

Areas covered: Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.

Expert opinion: Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.

导言:侵袭性脑膜炎球菌病(IMD)是一种罕见但可能致命的疾病,其流行病学通常被描述为不可预测和偶发性爆发:专家观点:在脑膜炎球菌特征和分类的背景下,研究了过去约 200 年间脑膜炎球菌流行病学和疫苗使用情况,以指导未来的脑膜炎球菌病预防工作:专家观点:历史和当代数据凸显了脑膜炎球菌流行病学的动态性质,高侵袭性克隆和受影响地区不断涌现。最近的变化包括全球 W 血清群疾病、脑膜炎球菌抗菌药耐药性 (AMR) 和脑膜炎球菌尿道炎的增加;此外,在取消 COVID-19 限制后,未接种疫苗的人群再次发病。尽管发生了这些变化,但对脑膜炎球菌流行病学的仔细分析表明,A、B、C、W 和 Y 血清群始终占主导地位,婴幼儿、青少年/年轻成人和老年人的 IMD 感染率较高。目前已有针对所有 5 个主要致病血清群的明显有效的疫苗,预防性使用这些疫苗是抗击 IMD(包括 AMR)的有力武器。世界卫生组织到 2030 年消除脑膜炎的目标要求广泛预防 IMD,这反过来又表明迫切需要在主要致病血清群和与年龄相关的风险群体中扩大脑膜炎球菌疫苗接种计划。
{"title":"The important lessons lurking in the history of meningococcal epidemiology.","authors":"Ray Borrow, Jamie Findlow","doi":"10.1080/14760584.2024.2329618","DOIUrl":"10.1080/14760584.2024.2329618","url":null,"abstract":"<p><strong>Introduction: </strong>The epidemiology of invasive meningococcal disease (IMD), a rare but potentially fatal illness, is typically described as unpredictable and subject to sporadic outbreaks.</p><p><strong>Areas covered: </strong>Meningococcal epidemiology and vaccine use during the last ~ 200 years are examined within the context of meningococcal characterization and classification to guide future IMD prevention efforts.</p><p><strong>Expert opinion: </strong>Historical and contemporary data highlight the dynamic nature of meningococcal epidemiology, with continued emergence of hyperinvasive clones and affected regions. Recent shifts include global increases in serogroup W disease, meningococcal antimicrobial resistance (AMR), and meningococcal urethritis; additionally, unvaccinated populations have experienced disease resurgences following lifting of COVID-19 restrictions. Despite these changes, a close analysis of meningococcal epidemiology indicates consistent dominance of serogroups A, B, C, W, and Y and elevated IMD rates among infants and young children, adolescents/young adults, and older adults. Demonstrably effective vaccines against all 5 major disease-causing serogroups are available, and their prophylactic use represents a powerful weapon against IMD, including AMR. The World Health Organization's goal of defeating meningitis by the year 2030 demands broad protection against IMD, which in turn indicates an urgent need to expand meningococcal vaccination programs across major disease-causing serogroups and age-related risk groups.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140189626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. 间隔 10 年加强接种 TBE 疫苗的证据:对当前数据的评估。
IF 6.2 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2024-02-16 DOI: 10.1080/14760584.2024.2311359
Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen

Introduction: Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.

Areas covered: We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms 'Encephalitis, Tick-Borne/prevention and control' and 'Vaccination' for articles published in the English language.

Expert opinion: Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3-5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions.

导言:蜱传脑炎(TBE)正在欧洲许多地区迅速蔓延。虽然接种疫苗仍是预防该疾病的最有效方法,但在许多流行国家,疫苗的接种率很低:我们对 MEDLINE 数据库进行了文献检索,以确定 2018 年至 2023 年间发表的、对间隔 10 年注射加强剂量的结核病疫苗(尤其是 Encepur)的免疫原性和有效性进行评估的文章。我们在PubMed上以MeSH术语 "脑炎,蜱传/预防和控制 "和 "疫苗接种 "检索了以英文发表的文章:恩斯普的长期免疫原性数据以及欧洲两种蜱媒脑炎疫苗--恩斯普和FSME-Immun的疫苗有效性和突破性感染的实际数据表明,将加强免疫间隔从3-5年延长至10年不会对蜱媒脑炎的保护产生负面影响,而与年龄无关。这种延长不仅简化了疫苗接种计划,还可能提高流行地区居民的疫苗接种率和依从性。
{"title":"Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.","authors":"Jörg Schelling, Suzanne Einmahl, Ralph Torgler, Carsten Schade Larsen","doi":"10.1080/14760584.2024.2311359","DOIUrl":"10.1080/14760584.2024.2311359","url":null,"abstract":"<p><strong>Introduction: </strong>Tick-borne encephalitis (TBE) is rapidly spreading to new areas in many parts of Europe. While vaccination remains the most effective method of protection against the disease, vaccine uptake is low in many endemic countries.</p><p><strong>Areas covered: </strong>We conducted a literature search of the MEDLINE database to identify articles published from 2018 to 2023 that evaluated the immunogenicity and effectiveness of TBE vaccines, particularly Encepur, when booster doses were administered up to 10 years apart. We searched PubMed with the MeSH terms 'Encephalitis, Tick-Borne/prevention and control' and 'Vaccination' for articles published in the English language.</p><p><strong>Expert opinion: </strong>Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3-5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases, SLIPE. 登革热的地区分子流行病学以及通过使用疫苗优化控制的可能性。拉丁美洲儿科传染病学会虫媒病毒委员会(SLIPE)的报告。
IF 5.5 3区 医学 Q1 IMMUNOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-29 DOI: 10.1080/14760584.2024.2395550
Jaime R Torres, Jose Brea-Del Castillo, Xavier Saez-Llorens, María L Ávila-Agüero, Wilfrido Coronell R, Celia Martinez-De Cuellar, Roberto Debbag

Introduction: Dengue disease represents a large and growing global threat to public health, accounting for a significant burden to health systems of endemic countries. The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) and the European Medicines Agency (EMA) currently recommend the use of TAK-003 dengue vaccine in high dengue burden and transmission settings for countries considering vaccination as part of their integrated management strategy for prevention and control of Dengue.

Areas covered: This paper describes the main conclusions of a workshop held by the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases (SLIPE) in November 2023, to generate consensus recommendations on the introduction of this new vaccine in the region. Considerations were made regarding the molecular epidemiology of dengue infection in the Americas and the need for more precise phylogenetic classification and correlation with clinical outcome and disease severity.

Expert opinion: Introduction of dengue vaccine should be considered as an strategy for health entities in the region, with participation of social sectors, scientific societies, and ministries of health that could be able to create a successful vaccination program.

导言:登革热病是全球公共卫生面临的一个巨大且日益严重的威胁,给登革热流行国家的卫生系统造成了沉重负担。世界卫生组织(WHO)战略专家咨询小组(SAGE)和欧洲药品管理局(EMA)目前建议,在登革热高负担和传播环境下,考虑将疫苗接种作为登革热预防和控制综合管理战略一部分的国家使用 TAK-003 登革热疫苗:本文介绍了拉丁美洲儿科传染病学会(SLIPE)臂瘤病毒委员会于 2024 年 11 月举办的研讨会的主要结论,该研讨会旨在就在该地区引入这种新型疫苗提出一致建议。专家们考虑了美洲登革热感染的分子流行病学、更精确的系统发育分类的必要性以及与临床结果和疾病严重程度的相关性:专家意见:引入登革热疫苗应被视为该地区卫生机构的一项战略,社会部门、科学协会和卫生部都应参与其中,以便成功制定疫苗接种计划。
{"title":"Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases, SLIPE.","authors":"Jaime R Torres, Jose Brea-Del Castillo, Xavier Saez-Llorens, María L Ávila-Agüero, Wilfrido Coronell R, Celia Martinez-De Cuellar, Roberto Debbag","doi":"10.1080/14760584.2024.2395550","DOIUrl":"10.1080/14760584.2024.2395550","url":null,"abstract":"<p><strong>Introduction: </strong>Dengue disease represents a large and growing global threat to public health, accounting for a significant burden to health systems of endemic countries. The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) and the European Medicines Agency (EMA) currently recommend the use of TAK-003 dengue vaccine in high dengue burden and transmission settings for countries considering vaccination as part of their integrated management strategy for prevention and control of Dengue.</p><p><strong>Areas covered: </strong>This paper describes the main conclusions of a workshop held by the Arbovirus Committee of the Latin American Society of Pediatric Infectious Diseases (SLIPE) in November 2023, to generate consensus recommendations on the introduction of this new vaccine in the region. Considerations were made regarding the molecular epidemiology of dengue infection in the Americas and the need for more precise phylogenetic classification and correlation with clinical outcome and disease severity.</p><p><strong>Expert opinion: </strong>Introduction of dengue vaccine should be considered as an strategy for health entities in the region, with participation of social sectors, scientific societies, and ministries of health that could be able to create a successful vaccination program.</p>","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Review of Vaccines
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1